Colorectal cancer is the third most common cancer worldwide, with 1.36 million people
diagnosed in 2012. The prognosis of colorectal cancer is better with an earlier diagnosis …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Surgical resection is the only option of cure for patients with metastatic colorectal cancer
(CRC). However, the risk of recurrence within 18 mo after metastasectomy is around 75 …

The eukaryotic translation initiation factor 4E (eIF4E) is a potent oncogene that is found to be
dysregulated in 30% of human cancer, including colorectal carcinogenesis (CRC). ISIS …

Targeted therapies require information on specific defective signaling pathways or
mutations. Advances in genomic technologies and cell biology have led to identification of …

Background Undertreatment has been frequently reported in the elderly cancer patient
population. For this reason, we aimed to characterize adjuvant chemotherapy (AC) use …

Regorafenib is an oral multi-kinase inhibitor used as salvage therapy for metastatic
colorectal cancer (mCRC). We tested whether serum cytokine levels are associated with …

Liver metastases are often the dominant site of metastatic disease in colorectal cancer.
Selective internal radiation therapy (SIRT) involves embolising radiolabeled spheres (SIR …

Malignant small bowel obstruction (MSBO) that does not resolve with conservative
measures frequently leaves few treatment options other than palliative care. This single …

Background Since 2013, informative trials exploring the optimal use of available biologic
agents in the first-line setting of metastatic colorectal cancer (mCRC) have been presented …